Introduction
The ontology of the immune system defines it as a system that developed to discriminate self from nonself (e.g., viruses and bacteria). In this context, tumor immunity presents a conundrum. The answer is that the immune system is able to recognize and reject cancer but follows a paradigm of immune recognition of self and altered-self (Houghton, 1994) . Surprisingly, the large majority of the antigens characterized to date are unaltered-self-antigens. Even when alterations are single amino-acid changes or short de novo open reading frames, they occur in an unaltered self-background. Recognition of unaltered self-antigens is more difficult to explain. Self-antigens are by definition encoded by genes expressed by both cancer cells and their normal cell counterparts. For instance, the functional genome of melanoma cells almost completely reflects the genes expressed by normal melanocytes at the same stage of differentiation and similar physiologic context (e.g., proliferation). Cancer immunity exists because the immune system's repertoire contains autoreactive T and B cells that, when activated properly, may reject malignant cells that express unaltered or altered selfantigens. This reveals a new problem: autoimmunity. If autoreactive cells can reject cancer, will they reject normal tissue? Is it possible to uncouple tumor immunity from autoimmunity? Are the antigens for tumor immunity the same as for autoimmunity? We will address these questions by describing first the types of antigens recognized by the immune system, and second, the mechanisms elicited in the priming and effector phases of tumor rejection. Finally we will describe the mechanisms involved in the immunological responses in autoimmunity and how this knowledge may be applied for new immunotherapies.
Tumor antigens
There is extensive evidence indicating that the immune system can recognize and destroy tumors. The specific antigens targeted are heterogeneous in their composition and distribution. Antibodies recognize carbohydrate motifs (Lloyd, 1991) , and antibodies and T cells recognize protein entities (Disis et al., 1994) . The antigens may be overexpressed in tumors and in immunoprivileged tissues or expressed in malignant cells and their normal tissue counter part. The controversy of a single classification for tumor antigens reflects this complexity. We propose that antigens (identified to date) can be divided into four groups: unique antigens, germ cell antigens (cancer-testis), differentiation antigens and overexpressed antigens ( Table 1 ) (recognizing that a classification of tumor antigens based on patterns of expression and antigen structure will evolve).
Unique tumor antigens
Mutations in genes may create new gene products with or without altered function. A single point mutation may activate an oncogene (e.g., ras, b-raf ) or inactivate a tumor suppressor gene (e.g., CDK4, p53). Some of these mutations may create new antigenic epitopes and become immunogenic (altered self-antigen). Polypeptides with single amino-acid mutations may become immunogenic by enhancing binding to either specific immunoglobulins, T-cell receptors (TCR) or MHC molecules. Boon et al., more than a decade ago, described that a nucleotide point mutation encoding a single amino-acid change could be recognized by CD8+lymphocytes through enhanced binding to MHC (Lurquin et al., 1989) . Furthermore, it has recently been established that the immune system can recognize products of alternative transcripts from cryptic start sites, alternative splicing, novel open reading frames, pseudogenes (Moreau-Aubry et al., 2000) and even products of antisense strands of DNA (Van Den Eynde et al., 1999) .
In melanoma, b-catenin and CDK4 are examples of genes with mutations that encode potentially oncogenic proteins. In one patient, a line of cytotoxic lymphocytes (CTL) derived from tumor infiltrating lymphocytes (TIL) was able to recognize a single amino-acid change, a serine to phenylalanine at position 37 of b-catenin in the context of HLA-A*24 (Robbins et al., 1996) . b-catenin is involved in cell adhesion and regulating signaling pathways for growth that are involved in malignant transformation. Mutations in exon 3 of b-catenin are rare in cutaneous melanoma (Demunter et al., 2002) . In another patient with metastasic melanoma treated at Memorial Sloan Kettering Cancer Center in New York, autologous CD8+cells recognized a mutant form of CDK4 that was resistant to p16/INK4a inhibition (Wolfel et al., 1995) . CDK4 is a crucial regulator of cell-cycle progression through the G1 phase and is negatively regulated by the cell-cycle inhibitor p16/INK4a. It is important to note that both CDK4 and p16/INK4a are linked with familial forms of melanoma, implicating them directly in oncogenesis. Another cellcycle regulator recognized by T cells of a melanoma patient is CDC27, an anaphase-promoting regulator (Wang et al., 1999) . In this case, the mechanism is slightly different. A mutation at the phosphorylation site induces trafficking of the protein to the endosomal compartment for degradation. This post-translational modification allows for presentation of a conserved epitope on class II MHC molecules and recognition by CD4+T cells. Another example of generation of a new class II epitope comes from identification of a mutation in the glycolytic enzyme triosephosphate isomerase in tumor cells from a melanoma patient (Pieper et al., 1999) . The HLA-DRB1*0101-restricted epitope was created by a mutation that converts a threonine residue to isoleucine, increasing T-cell agonist properties. Autologous CD4+cells derived from the patient are able to recognize the new epitope more efficiently (by several log 10 ) than the wild-type epitope.
Germ cell antigens
Germ cell antigens are normally expressed in male germ cells and are silenced in healthy somatic cells, but are reexpressed in certain cancers. The first melanoma antigen identified as a CD8+target (in this case in an HLA-A1 context) was MAGE-1 (van der Bruggen et al., 1991) . Since then, a number of germ cell antigens have been identified, including members of the MAGE, GAGE and BAGE families. Most of the epitopes identified in these families are class I restricted (Lucas et al., 2000) . Only recently has the physiological role of a MAGE gene been described. The MAGE-D1 gene product is involved in cell-cycle progression and apoptosis. It binds p75 neurotrophin and blocks cell-cycle progression and enhances apoptosis (Barker and Salehi, 2002) .
Germ cell antigens were initially identified in melanoma cells, but importantly are also expressed broadly in other cancer types. An antigen cloned from an esophageal cancer, NY-ESO-1, is a germ cell antigen that has both class I and II restricted 
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Immunity to melanoma T Ramirez-Montagut et al epitopes (Jager et al., 2000; Zeng et al., 2000) . It is one of the most immunogenic antigens known thus far. A total of 50% of the patients whose tumors express NY-ESO-1 have autoantibodies. Antibody titer directly correlates to tumor burden; therefore, these antibodies must not be protective (Chen et al., 1997; Jager et al., 1999) .
Differentiation antigens
Antigens present in both tumor cells (melanoma) and also in their normal cellular counterpart (melanocytes) are differentiation antigens (Boyse and Old, 1969) . There are three types of differentiation antigens (Houghton et al., 1982) . The first group is comprised of type I melanosomal membrane proteins, which have enzymatic activity in the synthesis of melanin. Tyrosinase (gene product of the albino mouse locus) is the rate-limiting enzyme in melanin biosynthesis. Tyrosinase-related protein-1 (TYRP)-1/gp75 (brown locus) stabilizes tyrosinase, TYRP-2/DCT (slaty locus) is a DOPAchrome tautomerase and finally, gp100/pmel17 (silver locus) is involved in melanin polymerization. Their expression correlates with the early, intermediate and late stages of melanocyte differentiation (named differentiation antigens also because of this feature) (Houghton et al., 1987) . TYRP-1/gp75 was the first melanoma autoantigen identified at a molecular level and the first differentiation antigen that showed immunological recognition (Thomson et al., 1988; Vijayasaradhi et al., 1990) . Serum IgG antibodies from a melanoma patient were able to immunoprecipitate TYRP-1/gp75 (Mattes et al., 1983) . The observation that a protein involved in melanin synthesis was recognized by the immune system suggested that other members in this pathway could also be recognized. Following the discovery that TYRP1/gp75 was an immunogenic melanoma antigen, tyrosinase and other melanosomal membrane proteins were identified as carrying epitopes for recognition by T cells. Epitopes in tyrosinase, TYRP-1/gp75, TYRP-2 and gp100/ pmel17 have been identified. Gp100/pmel17 was first identified with monoclonal antibodies (Thomson et al., 1988) and subsequently class I (Bakker et al., 1994; Kawakami et al., 1994a; Castelli et al., 1998) and class II restricted epitopes were identified (Li et al., 1998) . Presence of CD8+cells that recognize this epitope may correlate to a better prognosis (Yamshchikov et al., 2001) . The HLA-A*0201 natural epitope for tyrosinase was identified by mass spectroscopy. The endogenously presented peptide differs by one amino acid (asparagine to aspartic acid) from the predicted peptide. This change, due to natural post-translational modification of the protein, strongly affects the immunogenicity of the epitope through higher affinity for an HLA-A*0201 (Skipper et al., 1996) . Melan-A/MART-1 is another antigenic melanosomal protein recognized by melanoma patients. The HLA-A*0201 immunodominant epitope for this antigen was identified (residues 27-35) by CTL screening (Kawakami et al., 1994b). Interestingly, T-cell recognition of Melan-A/MART-1 has been detected in 50% of melanoma patients, but this does not correlate with improved clinical outcome. Further studies suggest that CTL against Melan-A/MART-1 are selected during T-cell development in the thymus, and that these T cells naturally respond to a variety of epitopes including viral and bacterial, but also crossreact with Melan-A/MART-1 epitopes . Antigen silencing of Melan-A/Mart-1 has been described through transcriptional downregulation induced by soluble factors produced by melanoma cells at high density (RamirezMontagut et al., 2000; Kurnick et al., 2001) .
These melanosomal antigens are important because immune reactivity against them is observed in both healthy individuals and in melanoma patients. Both groups have the same frequency and intensity of CTL responses to tyrosinase, gp100/pmel17 and Melan-A/ Mart-1 . This suggests that the immune repertoire contains T cells that recognize these self-antigens at a measurable frequency and that frequency of these T cells is similar in melanoma patients and healthy controls. These observations and others strongly suggest that, despite an immune repertoire that is capable of recognizing melanoma, spontaneous immunity against melanoma during tumor progression is rare.
The second group of differentiation antigens is the gangliosides (GM3, GD2, GM2 and O-acetyl GD3). These are carbohydrate antigens that are anchored to the membrane via a hydrophobic ceramide group and expose an extracellular sugar head group that is negatively charged by sialic acids. There is diversity in both the structure of the neutral sugar head group and in the amount of negative charge conferred by the sialic acids. The restricted tissue distribution and immunogenicity of these antigens makes them potential targets for immunotherapy. GM2, GD2 and GD3 are expressed in neuroectoderm-derived cells, such as melanocytes and melanomas (Hamilton et al., 1993) . Of these, GM2 is the most immunogenic, and natural antibodies have been found in 5% of patients with melanoma and a similar proportion of healthy individuals (Houghton et al., 1980) . Importantly, high liters correlate with a better prognosis . Although GD3 is the most highly expressed ganglioside and can be upregulated more than 10 000-fold in the process of malignant transformation (Albino et al., 1992) , its immunogenicity is low (Ritter et al., 1991) . However, passive transfer of antibodies against GD3 in patients with melanoma can induce major responses, even in large visceral tumors (Houghton et al., 1985; Vadhan-Raj et al., 1988) .
Overexpressed antigens
Recently, a class II restricted epitope in the context of HLA-DRB1*1101 was described for EphA3. No mutations were identified in the EphA3 gene sequence but the gene product was clearly overexpressed in several tumor types including melanoma, lung carcinoma and sarcoma (Chiari et al., 2000) . EphA3, a member of the Eph family of tyrosine kinase receptors, mediates the repulsion of neural cells from cells carrying the ligand (ephrins) on their surfaces. It has been suggested that disregulation of the ephrin receptors may be involved in tumorigenesis by perpetuating autocrine loops.
Immune responses to melanoma (see Table 2 )
Many oncologists believe that spontaneous regressions of melanoma are more common than other types of cancer (except for renal cell carcinoma). Because melanoma frequently metastasizes to the skin and contains pigment, it is readily detected even when small. Therefore, frequency of 'spontaneous regressions' may appear artifactually high when compared to other more 'internal' cancers. Also, the fact that melanoma cells are easily cultured as cell lines has allowed for the study of autologous immune responses in vitro with greater ease than other tumor types. The observation that metastatic melanoma can respond to immunotherapies such as monoclonal antibodies, interferons and interleukin-2 has certainly fueled the notion that melanoma is a 'special case', but in fact response rates are quite low (o20% of patients) and it is hard to draw conclusions about the relative immune responsiveness of melanoma. As more information emerges about antigens recognized in other types of cancers, we predict that the lessons learned from studying melanoma will carry over to other cancers. Animal models, where experimental conditions and genetic variability can be controlled, have provided compelling evidence that immunity to melanoma can be effectively induced. Immunity can proceed through both antibody-mediated and T-cellmediated pathways.
Antibody-mediated responses
In our laboratory, antibody responses to the differentiation antigen TYRP-1/gp75 have been thoroughly studied (Vijayasaradhi et al., 1990) . The mouse model is based on the melanoma cell line B16, a cell line derived from a spontaneous tumor in a C57BL/6 mouse.
It is highly aggressive, but more importantly, similar to human melanoma in its propensity for metastasis and low MHC expression. B16 has low inherent immunogenicity. TYRP-1/gp75 is expressed in B16, mainly bound to the melanosomal membranes in an intracellular compartment; however, approximately 2% of the protein at steady state is expressed on the plasma membrane . A mouse monoclonal antibody, TA99 (IgG2a), raised against human TYRP-1/gp75 also recognizes the mouse orthologue (80% homology between both proteins) and has no direct effect on B16 cell growth. This model allowed us to explore two questions. First, is it possible to induce tumor rejection by passive transfer of mouse antibody and, if so, what are the requirements for antibodymediated rejection? Second, is it possible to induce active antibody responses against TYRP-1/gp75 that reject melanoma?
Passive immunization with antibody against TYRP-1/ gp75 results in rejection of challenge with syngeneic melanoma (Hara et al., 1995) . Subcutaneous and intradermal challenges with B16 tumor cells could be rejected. In a metastatic model, where cells that are injected intravenously form lung metastases, passive immunization with antibody decreased lung metastasis even when its administration was delayed for up to 7 days. The requirements for melanoma rejection were studied by depleting specific populations of cells from the adaptive and innate immune systems. It was shown that CD4+cells were required for protection from lung metastases and that NK cells had a natural immune effect against B16 tumor growth both in lung and subcutaneous tissue. To address the molecular requirements for rejection, the lung metastasis experiments were repeated in mice genetically deficient for FcgR. FcgR types I and III are activation receptors that signal through the g chain and are expressed in macrophages and NK cells. FcgR-deficient mice lack FcRgI and III. FcgRI exerts its effector function when it binds its ligand Fc, especially Fc of IgG2a molecules. Intravenous challenge of B16 in FcgR-deficient mice showed no abrogation of lung metastases following (Clynes et al., 2000) . This supports the notion that antibody-mediated protection against B16 is dependent on activation of FcgR on macrophages. These results confirmed that antibody immunity against a differentiation antigen (TYRP-1/gp75) can elicit tumor rejection. However, it remained to be established if active immunization could induce antibodies that reject B16. To induce immune responses against TYRP-1/gp75, or any other differentiation antigen, tolerance or ignorance must first be broken because antibodies to TYRP-1/gp75 are not elicited in B16 bearing mice. The strategy used to break tolerance was presentation of the antigen to the host as 'altered self '. The first experimental approach was to immunize mice with TYRP-1/gp75 produced in insect cells (baculovirus system) . Mice challenged with B16 tumor cells were protected and this protection could be transferred by serum. The antigen in the Sf-9 vaccine was an insoluble early-processed form of TYRP-1/gp75 (similar to the immature form localized in the endoplasmic reticulum), yet the immune sera recognized mature full-length TYRP-1/gp75 (localized in the post-Golgi compartment of the secretory pathway). This demonstrated that TYRP-1/gp75 presented to the host as 'altered self' could break tolerance and induce the recognition of wild-type TYRP-1/ gp75 and the production of protective antibodies against B16.
A second approach to breaking tolerance against TYRP-1/gp75 was to administer a xenogeneic orthologue of the protein by active immunization . Two different forms of protein were designed. Xenogeneic immunization was done with either lysates of the human melanoma cell line SK-MEL-19 or purified human TYRP-1/gp75 protein in Freund's adjuvant. These vaccines induced autoantibodies that recognized mouse gp75 in C57BL/ 6 mice, and immunization with SK-MEL-19 induced antibodies that mediated rejection of B16 melanoma cells.
A third approach to present TYRP-1/gp75 as 'altered self ' to the immune system employed xenogeneic DNA immunization . In this case, genetic immunization was comprised of human and/ or mouse TYRP-1/gp75 genes coated onto gold particles that were used for skin injection using a gene gun. The gold particles localize DNA in cutaneous tissues, potentially transfecting cutaneous antigen-presenting cells and other cutaneous cells (for potential crosspresentation to professional antigen-presenting cells (APC)).
Five immunizations with mouse TYRP-1/gp75 DNA in C57BL/6 mice did not generate an antibody response to the protein or protect mice from challenge with B16 melanoma. The same immunization scheme with human instead of mouse TYRP-1/gp75 DNA induced antibodies to mouse TYRP-1/gp75 and protection from B16 challenge (more than 80% reduction in lung metastasis when compared to control mice) . Importantly, two immunizations with human TYRP-1/ gp75 DNA followed by one immunization with the mouse gene led to an improved antibody response compared to three immunizations with the human gene. Increased antibody production with this immunization schedule suggests that the initial immunizations with the human gene broke tolerance to the mouse antigen and that the immune response was not because of crossreactivity of antibodies. To study the requirements for immune rejection, depletion experiments were performed. Results again showed a CD4+, NK1.1+and FcgR dependence. Experiments done in CD4-deficient mice showed no antibody response or tumor rejection, demonstrating that CD4+cells are necessary at the priming phase of the immune response . This CD4+requirement suggests that the human TYRP-1/gp75 gene product generates new epitopes that are presented on the MHC class II molecule and are probably recognized by Th2 cells. In the mouse protein, there are epitopes that are glycosylated and probably not processed and presented (Qin, unpublished data). These cryptic epitopes are presumably uncovered nonglycosylated products that are processed to activate CD4+cells that provide help for B-cell antibody responses.
CD8+T-cell-mediated tumor immunity
The immune repertoire of T cells is primarily established in the thymus. High-affinity autoreactive T cells are actively deleted (negative selection) and T cells with low affinity for self-MHC die by neglect (lack of positive selection). Therefore, the final repertoire consists of intermediate T cells presumably selected against reactivity for self-peptides. However, it is now clear that the immune repertoire also contains autoreactive lowaffinity T cells that escape thymus deletion and can recognize endogenous epitopes. The current paradigm of CTL activation is the two-signal model. The first signal is binding of the T-cell receptor (TCR) to an MHC : peptide complex. The second signal is costimulatory, produced by cytokines and binding to surface molecules on the APC. Once a CTL is activated it will lyse cells that express the cognate MHC:peptide complex on its surface, even when the peptide binds weakly to the MHC molecule. Since most tumor antigens are self-antigens, high-affinity T cells will either be deleted in the thymus or remain ignorant or become tolerant in the periphery.
Activation of circulating low-affinity self-reactive CTLs becomes a challenge for tumor immunologists. A strategy was developed by Dyall et al. (1998) where engineered peptides that bind more strongly to the MHC molecule than to the original peptide seem to be efficient enough to prime low-affinity T cells. These activated CTLs will recognize the original epitope despite its low affinity for MHC and lyse the target cells expressing the original peptide. Using mouse TYRP-1/gp75 as a target antigen, the TWHRYHLL peptide (TYRP-1/gp75 222-229 ), a peptide binding weakly to the class I MHC molecule K b was identified. Two bulky amino acids that form minor anchor residues facing the MHC-binding groove were substituted with smaller, better fitting residues. The new peptide TAYRYHLL (Trp to Ala and His to Tyr substitutions) not only had higher affinity for the K b but also protected mice from B16 tumor challenge following peptide immunization. In vitro studies showed that a CTL line generated against the TAYR-YHLL peptide could recognize and lyse cells pulsed with the original TWHRYHLL peptide, and more importantly, that syngeneic melanoma cell lines naturally process and express TWHRYHLL. These results demonstrate that optimizing nonimmunogenic peptides into better MHC or TCR binders can elicit a CTL response against wild-type peptides and induce tumor rejection (Dyall et al, 1998) .
A second strategy to overcome tolerance of self is xenogeneic immunization. In contrast to TYRP-1/gp75, immune responses elicited against other differentiation antigens in C57BL/6 mice, including human TYRP-2/ DCT and human gp100/pmel17, are T-cell-mediated (Bowne et al., 1999; Hawkins et al., 2000) . Mice immunized with the human TYRP-2/DCT gene were protected from B16 lung metastasis. Tumor rejection required CD8+cells at the effector phase but not antibodies or NK cells. Tumor protection was also present in B-cell-deficient mice and surprisingly, in mice deficient in perforin and Fas ligand (Bowne et al., 1999) . This shows that the CD8+effector mechanisms in this model still need to be determined.
Studies addressing the requirements for the priming phase demonstrated CD4+and interferon gamma (IFN-g) dependence (Wolchok et al., 2001) . Mice deficient in IFN-g were not protected by human TYRP-2/DCT immunization. Administration of recombinant IFN-g concomitantly with immunization restored tumor protection. This established the requirement for IFN-g in the priming of CD8+ cells.
A second differentiation antigen that elicits a CTLdependent response is gp100/pmel17 (Hawkins et al., 2000) . Mice immunized with human gp100/pmel17 DNA are partially protected from B16 challenge (60-70% protection). Experiments in class I and class II-deficient mice demonstrated a requirement for CD8+cells only. Mice lacking CD4+cells (class II-deficient) still rejected B16 tumors, indicating that these cells are not necessary for the priming or effector phases, although tumor immunity was more effective in the presence of CD4+T cells. To establish if compensatory mechanisms were functioning in class II-deficient mice (such as IFN-g overproduction), wild-type mice were depleted of CD4+T cells during genetic immunization with human gp100/pmel17. Mice depleted of CD4+T cells were still protected against B16 challenge indicating a CD4+T-cell-independent mechanism of CD8+T-cell priming (Hawkins et al., 2000) .
These mouse studies demonstrate that rejection of melanoma can be induced by different immunological mechanisms. We have shown that tumor antigens presented to the immune system as altered self can break tolerance and induce tumor immunity. One strategy for altered self is the creation of heteroclitic epitopes with increased affinity for MHC or TCR. Heteroclitic immunization can activate low-affinity autoreactive T cells, while xenogeneic immunization with differentiation antigens can recruit several components of the immune system (Table 2) and induce tumor rejection. However, one potential consequence of immune reactions directed against selfantigens is damage to normal tissue that expresses the antigen.
Autoimmune responses in melanoma (see Table 2 )
Immunization against differentiation antigens results in melanocyte destruction and can be visualized as coatcolor depigmentation (vitiligo). Studies in our laboratory have demonstrated that tumor immunity and autoimmunity may follow different pathways and have different requirements.
Antibody mediated autoimmunity
Passive immunization against TYRP-1/gp75 using mouse antibody provided the first evidence for different effector pathways (Hara et al., 1995) . TA99 at a dose of 37.5-150 mg protected mice from tumor challenge without any evidence for autoimmunity. Signs of hypopigmentation were observed only when doses of TA99 were escalated up to 300-1000 mg. Thus, the threshold dose of TA99 required for coat-color changes was fivefold greater than the threshold required for tumor immunity. Surprisingly, the effector cells responsible for depigmentation included a Thy1+population (Hara et al., 1995) . Recently, the pathogenesis of antibody-mediated vitiligo has been characterized (Trcka et al., 2002) . Two redundant and alternative pathways can mediate vitiligo in this model, involving either FcgR or complement systems. Experiments in mice deficient in FcgR or the C3 component of complement showed hypopigmentation following passive antibody immunization, whereas mice deficient in both components did not develop autoimmune hypopigmentation. Redundancy was then established with bone marrow chimeric mice. When double knockout mice were transplanted with bone marrow from singledeficient donors and passively immunized with TA99, the recipients depigmented. Depigmentation could be reconstituted by transfer of macrophages with active FcgR. This showed that depigmentation could be mediated by macrophages and in the absence of functional FcgR, the complement system could act as an alternative pathway. Therefore, it is possible to uncouple autoimmunity from tumor immunity. Tumor immunity is FcgR dependent while depigmentation is FcgR/complement mediated.
Active immunization against human gp75 induces an antibody response that requires activating FcR I and III for tumor rejection, while depigmentation proceeded in the absence of activating FcR I and III . Presumably the mechanism is also FcgR and C3 redundant.
T-cell-mediated autoimmunity
Mouse experiments indicated that TYRP-2/DCT tumor immunity requires CD4+/IFN-g at the priming phase and CD8+but not perforin at the effector phase (Bowne et al., 1999; Wolchok et al., 2001 ). In this model, depigmentation still depended on CD4+/IFN-g for immunization but required the presence of both CD8+and perforin for autoimmunity. Interestingly, absence of the Th2-type cytokine IL-4 accelerated autoimmunity. Tumor immunity and autoimmunity induced by genetic immunization with human gp100/ pmel17 DNA had similar immune requirements (Hawkins et al., 2000) . In both instances, CD8+cells were essential for tumor rejection and depigmentation. In another model, using mice transgenic for HLA-A*0201 and deficient in mouse tyrosinase, CTLs against a tyrosinase epitope were generated. Adoptive transfer of these T cells resulted in autoimmune depigmentation in mice expressing tyrosinase, showing that CD8+cells were sufficient for autoimmunity against this differentiation antigen (Colella et al., 2000) .
These results show that tumor immunity and autoimmunity can be uncoupled and that the threshold for autoimmunity can be higher than for tumor immunity, at least in selective circumstances. With this in mind, new strategies are possible to induce tumor immunity in the absence of autoimmunity.
Concluding remarks
Cancer immunology faces two challenges. First is the generation of effective immune responses against selfantigens expressed on tumor cells. Second, if recognition of self-antigens can reject tumor cells, how can we decrease destruction of normal tissues expressing the same antigens? Understanding the mechanisms of tumor rejection and autoimmunity at a cellular and molecular level may show us the way.
Induction of self-recognition is possible through the presentation of engineered self (e.g., heteroclitic immunization) or altered self (e.g., xenogeneic immunization) to the immune system. It remains to be determined if long-lived tumor immunity can be acquired. Down regulation of immune responses is expected because there will be immune tolerance in the presence of a constant antigenic load.
It is perhaps surprising that concomitant tumor immunity and autoimmunity might utilize different pathways in their priming and effector phases. New strategies may be developed to optimize immunization for tumor rejection while preserving tolerance of normal tissues.
Further studies should help to elucidate what determines the segregation of tumor immunity from autoimmunity effector mechanisms for antigens that have more than 80% homology (e.g., humoral in TYRP-1/gp75 vs cellular in TYRP-2/DCT immunizations). Minor differences in amino-acid sequences, costimulation requirements, tumor microenvironment and even differences in the body compartments where tumors are sustained may account for different effector pathways.
